← All trials
NCT06946225
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 25, 2025
- Primary completion
- Aug 31, 2029
- Completion date
- Aug 31, 2029
- First posted
- Apr 27, 2025
- Last posted
- Oct 27, 2025
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- immatics Biotechnologies GmbHLead sponsor
- Moderna TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.